MaxCyte, Inc. (NASDAQ:MXCT) Holdings Lifted by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC grew its position in MaxCyte, Inc. (NASDAQ:MXCT) by 4.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 699,089 shares of the company’s stock after purchasing an additional 30,209 shares during the period. Silvercrest Asset Management Group LLC owned approximately 0.67% of MaxCyte worth $2,929,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. bought a new position in MaxCyte in the 4th quarter worth about $29,000. Russell Investments Group Ltd. bought a new position in MaxCyte in the 1st quarter worth about $28,000. Nisa Investment Advisors LLC grew its position in MaxCyte by 47,100.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after purchasing an additional 11,775 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in MaxCyte by 350.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $56,000 after purchasing an additional 9,323 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in MaxCyte by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock worth $58,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Insider Activity at MaxCyte

In related news, EVP Thomas M. Ross sold 13,531 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $4.03, for a total transaction of $54,529.93. Following the completion of the sale, the executive vice president now directly owns 25,000 shares of the company’s stock, valued at $100,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Thomas M. Ross sold 13,531 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $4.03, for a total transaction of $54,529.93. Following the completion of the sale, the executive vice president now directly owns 25,000 shares of the company’s stock, valued at $100,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Joseph Johnston sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $3.99, for a total transaction of $39,900.00. Following the sale, the director now directly owns 141,950 shares of the company’s stock, valued at $566,380.50. The disclosure for this sale can be found here. Insiders sold a total of 56,864 shares of company stock valued at $230,762 over the last ninety days. Insiders own 3.00% of the company’s stock.

MaxCyte Trading Up 0.2 %

Shares of MaxCyte stock traded up $0.01 on Tuesday, hitting $4.64. The company had a trading volume of 91,960 shares, compared to its average volume of 586,809. The business has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $4.46. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The business had revenue of $11.34 million during the quarter, compared to analysts’ expectations of $7.75 million. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. As a group, equities research analysts expect that MaxCyte, Inc. will post -0.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a report on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.